Belgium-based agri-tech company Biotalys, which specialises in biological crop protection products, has appointed Simon Moroney as chairman of its board.

Mr Moroney has over 30 years of industry leadership and research experience. He was co-founder and chief executive of biotechnology company MorphoSys, which he led to a $239m initial public offering on the Nasdaq stock exchange in 2018. He is sits on the Novartis board as a non-executive director.

“This appointment demonstrates our ambition to establish Biotalys at the forefront of innovation in agricultural technology,” says Biotalys chief executive Patrice Sellès. “Simon’s extensive experience and proven track record will be invaluable to our team as we continue to develop our pipeline of antibody-derived biocontrol solutions.

Biotalys has recently submitted regulatory dossiers to the EU and US regulatory authorities for its first protein-based biocontrol product, Evoca, a biofungicide with a novel mode of action to control key pathogens in selected fruit and vegetable crops.